Narita Hiroshi, Komori Kimihiro, Usui Akihiko, Yamamoto Kiyohito, Banno Hiroshi, Kodama Akio, Sugimoto Masayuki
Department of Vascular Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Vascular Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ann Vasc Surg. 2016 Jul;34:55-61. doi: 10.1016/j.avsg.2015.11.041. Epub 2016 May 12.
The advent of thoracic endovascular aneurysm repair (TEVAR) has bought about a tremendous revolution in the treatment strategy for aortic arch aneurysms. We reviewed our experience using TEVAR with the hybrid approach in the treatment of aortic arch aneurysms to evaluate its feasibility, safety, and effectiveness.
Between October 2008 and July 2014, 61 consecutive patients (51 men; mean age 75.8 ± 7.7 years; range, 43-85 years) underwent elective treatment for aortic arch aneurysms with the hybrid approach. The 61 patients were separated into 2 groups. Thirty-five patients underwent total debranching TEVAR for zone 0 (debranching TEVAR group), 26 patients underwent long elephant trunk (ET) followed by secondary retrograde TEVAR (ET group). Preoperative, perioperative, and follow-up data were collected retrospectively in the database.
The technical success rate was 100%. The paraplegia rates in total debranching TEVAR and long ET TEVAR and were 2.9% and 3.8%, respectively. The stroke rates in total debranching TEVAR and long ET TEVAR were 11.4% and 7.7%, respectively. The overall 30-day mortality and in-hospital mortality rates for all 61 patients were 0% and 3.4% (n = 2; both were in the total debranching TEVAR group), respectively. There were no perioperative type 1 or 3 endoleaks that required secondary intervention. The mean hospital stay was 15.8 days. The median follow-up was 309 ± 303 days. No aneurysm-related deaths occurred during follow-up.
The hybrid approach can be safely performed with good technical success and good midterm results. In future, new alternative devices for aortic arch pathologies, such as a branched stent graft that eliminates extra-anatomic bypass, should be developed.
胸主动脉腔内修复术(TEVAR)的出现给主动脉弓动脉瘤的治疗策略带来了巨大变革。我们回顾了采用杂交技术行TEVAR治疗主动脉弓动脉瘤的经验,以评估其可行性、安全性和有效性。
2008年10月至2014年7月,61例连续患者(51例男性;平均年龄75.8±7.7岁;范围43 - 85岁)采用杂交技术对主动脉弓动脉瘤进行择期治疗。61例患者分为2组。35例患者行0区完全去分支TEVAR(去分支TEVAR组),26例患者先行长象鼻支架置入术(ET),然后二期行逆行TEVAR(ET组)。术前、围手术期和随访数据均从数据库中进行回顾性收集。
技术成功率为100%。完全去分支TEVAR和长ET TEVAR的截瘫发生率分别为2.9%和3.8%。完全去分支TEVAR和长ET TEVAR的卒中发生率分别为11.4%和7.7%。61例患者总的30天死亡率和住院死亡率分别为0%和3.4%(n = 2;均在完全去分支TEVAR组)。围手术期无需要二次干预的Ⅰ型或Ⅲ型内漏。平均住院时间为15.8天。中位随访时间为309±303天。随访期间无动脉瘤相关死亡发生。
杂交技术可以安全实施,技术成功率高,中期效果良好。未来,应研发用于主动脉弓病变的新型替代装置,如无需解剖外旁路的分支型覆膜支架。